These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 32662333)

  • 21. Cyanobacterial metabolites as promising drug leads against the M
    Naidoo D; Roy A; Kar P; Mutanda T; Anandraj A
    J Biomol Struct Dyn; 2021 Oct; 39(16):6218-6230. PubMed ID: 32691680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease.
    C S; S DK; Ragunathan V; Tiwari P; A S; P BD
    J Biomol Struct Dyn; 2022 Feb; 40(2):585-611. PubMed ID: 32897178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive modeling by deep learning, virtual screening and molecular dynamics study of natural compounds against SARS-CoV-2 main protease.
    Joshi T; Joshi T; Pundir H; Sharma P; Mathpal S; Chandra S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6728-6746. PubMed ID: 32752947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition mechanism and hot-spot prediction of nine potential drugs for SARS-CoV-2 M
    Luo S; Huang K; Zhao X; Cong Y; Zhang JZH; Duan L
    Nanoscale; 2021 May; 13(17):8313-8332. PubMed ID: 33900318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M
    Kumar V; Dhanjal JK; Kaul SC; Wadhwa R; Sundar D
    J Biomol Struct Dyn; 2021 Jul; 39(11):3842-3854. PubMed ID: 32431217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1,2,4 triazolo[1,5-a] pyrimidin-7-ones as novel SARS-CoV-2 Main protease inhibitors: In silico screening and molecular dynamics simulation of potential COVID-19 drug candidates.
    Kavitha K; Sivakumar S; Ramesh B
    Biophys Chem; 2020 Dec; 267():106478. PubMed ID: 33022567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
    Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers.
    Rocha REO; Chaves EJF; Fischer PHC; Costa LSC; Grillo IB; da Cruz LEG; Guedes FC; da Silveira CH; Scotti MT; Camargo AD; Machado KS; Werhli AV; Ferreira RS; Rocha GB; de Lima LHF
    J Biomol Struct Dyn; 2022; 40(19):9214-9234. PubMed ID: 33970798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
    Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular docking and simulation studies on SARS-CoV-2 M
    Lokhande KB; Doiphode S; Vyas R; Swamy KV
    J Biomol Struct Dyn; 2021 Nov; 39(18):7294-7305. PubMed ID: 32815481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Kumar B; Parasuraman P; Murthy TPK; Murahari M; Chandramohan V
    J Biomol Struct Dyn; 2022 Oct; 40(17):7796-7814. PubMed ID: 33759690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Venetoclax: a promising repurposed drug against SARS-CoV-2 main protease.
    Ghosh S; Bhattacherjee D; Satpati P; Bhabak KP
    J Biomol Struct Dyn; 2022; 40(22):12088-12099. PubMed ID: 34424151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
    Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
    J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of bioactive molecule from
    Tripathi MK; Singh P; Sharma S; Singh TP; Ethayathulla AS; Kaur P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5668-5681. PubMed ID: 32643552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A computational study on active constituents of
    Shamsi S; Anjum H; Shahbaaz M; Khan MS; Ataya FS; Alamri A; Alhumaydhi FA; Husain FM; Rehman MT; Mohammad T; Islam A; Anjum F; Shamsi A
    J Biomol Struct Dyn; 2022 Oct; 40(17):7702-7713. PubMed ID: 33759703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.